Toxic epidermal necrolysis: Review of pathogenesis and management
Authors:
- Andrew DowneyADAndrew Downey
- Chris JacksonCJChris Jackson
- Nadia HarunNHNadia Harun
- Alan CooperACAlan Cooper
- 1 June 2012
- journal article
- review article
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 66 (6) , 995-1003
Abstract
No abstract availableKeywords
This publication has 77 references indexed in Scilit:
- New Insights in Toxic Epidermal Necrolysis (Lyellʼs Syndrome)Drug Safety, 2010
- Endothelial cell apoptosis in severe drug-induced bullous eruptionsBritish Journal of Dermatology, 2009
- A marked increase in serum soluble Fas ligand in drug-induced hypersensitivity syndromeBritish Journal of Dermatology, 2008
- Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis: Assessment of Medication Risks with Emphasis on Recently Marketed Drugs. The EuroSCAR-StudyJournal of Investigative Dermatology, 2008
- Effects of treatments on the mortality of Stevens-Johnson syndrome and toxic epidermal necrolysis: A retrospective study on patients included in the prospective EuroSCAR StudyJournal of the American Academy of Dermatology, 2008
- Glutathione-S-Transferase Pi Expression in Toxic Epidermal Necrolysis: A Marker of Putative Oxidative Stress in KeratinocytesSkin Pharmacology and Physiology, 2006
- Toxic Epidermal Necrolysis: Does Immunoglobulin Make a Difference?Journal of Burn Care & Rehabilitation, 2004
- Nitric Oxide: Cytotoxicity versus Cytoprotection— How, Why, When, and Where?Nitric Oxide, 1997
- The Glut athione S-Transferase Supergene Family: Regulation of GST and the Contribution of the lsoenzymes to Cancer Chemoprotection and Drug Resistance Part ICritical Reviews in Biochemistry and Molecular Biology, 1995
- Severe Adverse Cutaneous Reactions to DrugsNew England Journal of Medicine, 1994